跳至主要内容
临床试验/NCT00637442
NCT00637442Unknown不适用

Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

University Hospital, Bonn1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
30
试验地点
1
主要终点
Cerebral perfusion

研究概览

简要总结

Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
  • Underwritten study consent
  • No treatment with acetylcholinesterase inhibitors
  • Mini-Mental-State Examination: 12-25 points
  • Age: 50-80 Years
  • Orale contraception for women of child-bearing age

排除标准

  • Mental Disorders
  • Other Diseases of the CNS
  • Severe Illness
  • Contraindication for MRI-Scan
  • Contraindication for Galantamin (Reminyl retard®)
  • Participation at other clinical trials

研究组 & 干预措施

CASL-MRI

Experimental

Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl

干预措施: Reminyl retard (Drug)

结局指标

主要结局

Cerebral perfusion

时间窗: baseline and after 12 weeks

次要结局

  • Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog)(baseline, after 12 and 24 weeks)
  • Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)(baseline, after 12 and 24 weeks)
  • Neuropsychiatric Inventory (NPI)(baseline, after 12 and 24 weeks)
  • Mini-Mental-Status-Examination (MMSE)(baseline, after 12 and 24 weeks)

研究者

发起方
University Hospital, Bonn
申办方类型
Other

研究点 (1)

Loading locations...

相似试验